Eisai Company, Ltd. (ESALY.PK) Announces Launch of Antiepileptic Drug Fycompa In U.S.
1/30/2014 4:45:42 PM
Tokyo, Jan 6, 2014 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that on January 2, 2014, its U.S. subsidiary Eisai Inc. launched the AMPA receptor antagonist Fycompa (perampanel), a first-in-class antiepileptic drug (AED) discovered and developed In-house, in the United States as an adjunctive therapy for partial-onset seizures with or without secondary generalized seizures in patients with epilepsy aged 12 and older.
Help employers find you! Check out all the jobs and post your resume.
comments powered by